Loading...
XNASMURA
Market cap56mUSD
Dec 23, Last price  
3.29USD
1D
3.46%
1Q
2.81%
IPO
-13.42%
Name

Mural Oncology PLC

Chart & Performance

D1W1MN
XNAS:MURA chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-207m
L+3.71%
-175,433,000-200,030,000-207,447,000
CFO
-194m
L+15.22%
-156,668,000-168,588,000-194,249,000

Profile

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
URL
IPO date
Nov 03, 2023
Employees
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFY
2023‑122022‑122021‑12
Income
Revenues
Cost of revenue
194,638
196,686
176,839
Unusual Expense (Income)
NOPBT
(194,638)
(196,686)
(176,839)
NOPBT Margin
Operating Taxes
12,160
4,884
68
Tax Rate
NOPAT
(206,798)
(201,570)
(176,907)
Net income
(207,447)
3.71%
(200,030)
14.02%
(175,433)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
12,196
5,844
5,920
Long-term debt
23,920
32,928
44,692
Deferred revenue
Other long-term liabilities
304
356
Net debt
(234,994)
58,158
75,918
Cash flow
Cash from operating activities
(194,249)
(168,588)
(156,668)
CAPEX
(3,452)
(5,511)
(4,385)
Cash from investing activities
(3,452)
(5,511)
(4,385)
Cash from financing activities
468,811
174,099
161,053
FCF
(255,287)
(196,954)
Balance
Cash
270,852
(19,386)
(25,306)
Long term investments
258
Excess cash
271,110
Stockholders' equity
(30,690)
(21,656)
(17,879)
Invested Capital
315,614
19,690
25,662
ROIC
ROCE
10,004.37%
EV
Common stock shares outstanding
16,690
16,688
16,688
Price
5.92
 
Market cap
98,803
 
EV
(136,191)
EBITDA
(192,071)
(195,146)
(175,365)
EV/EBITDA
0.71
Interest
Interest/NOPBT